文献速递肿瘤 PET/CT甲状腺核医学

18F-DOPA与18F-FDG PET/CT在持续性或复发性甲状腺髓样癌中的诊断价值:降钙素与癌胚抗原截断值的重要性

Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-06-23

该前瞻性研究纳入18例复发性甲状腺髓样癌患者,比较18F-DOPA与18F-FDG PET/CT检测病灶的效能。18F-DOPA灵敏度66.7%高于18F-FDG的50%(p<0.01),且降钙素≥150 pg/mL时两种显像检出率均显著提高。18F-DOPA PET/CT在检测和定位病灶方面似乎优于18F-FDG。

要点

  • 18F-DOPA检出28个病灶,18F-FDG检出16个病灶,每例病灶数1.56±1.5 vs 0.89±1.18(p=0.01)。
  • 降钙素≥150 pg/mL组18F-DOPA灵敏度90.9% vs <150 pg/mL组28.6%(p=0.013)。
  • 降钙素≥150 pg/mL组18F-FDG灵敏度72.7% vs <150 pg/mL组14.3%(p=0.025)。

核心结论

  • 18F-DOPA PET/CT在检测和定位复发性甲状腺髓样癌病灶方面似乎优于18F-FDG PET/CT。
  • 该技术在其它影像学检查阴性且降钙素≥150 pg/mL或癌胚抗原≥5 ng/mL的患者中似乎尤其有用。

研究设计与样本

  • 前瞻性招募18例经降钙素或癌胚抗原升高确定的复发性甲状腺髓样癌患者。
  • 每例患者均接受18F-FDG PET/CT和18F-DOPA PET/CT检查。

主要发现

  • 18F-DOPA检出异常摄取12例,18F-FDG检出9例,灵敏度66.7% vs 50%(p<0.01)。
  • 18F-DOPA检出28个病灶,18F-FDG检出16个病灶,每例病灶数1.56±1.5 vs 0.89±1.18(p=0.01)。
  • 与18F-DOPA相比,没有患者经18F-FDG检出额外病灶。
  • 降钙素≥150 pg/mL组 vs <150 pg/mL组:18F-DOPA灵敏度90.9% vs 28.6%(p=0.013),18F-FDG灵敏度72.7% vs 14.3%(p=0.025)。
  • 采用癌胚抗原≥5 ng/mL截断值时,18F-DOPA和18F-FDG PET/CT的检出率分别为81.1%和72.7%。

关键数值与推荐

  • 美国甲状腺协会指南设定降钙素150 pg/mL截断值用于进一步影像学检查(包括18F-DOPA PET/CT),本研究评估了该截断值的可靠性。
  • 降钙素≥150 pg/mL时18F-DOPA灵敏度90.9%,<150 pg/mL时28.6%(p=0.013)。
  • 降钙素≥150 pg/mL时18F-FDG灵敏度72.7%,<150 pg/mL时14.3%(p=0.025)。
  • 癌胚抗原≥5 ng/mL时18F-DOPA检出率81.1%,18F-FDG检出率72.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study sought to evaluate and compare the utility of 18-F-fluorodihydroxyphenylalanine (18F-DOPA) and 18-F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for identification of lesions in patients with recurrent medullary thyroid carcinoma (MTC). In addition, we analyzed the correlation between the calcitonin (Ct), carcinoembryonic antigen (CEA) levels, each doubling time (DT), and PET positivity. We evaluated the reliability of the 150 pg/mL Ct cutoff set by the American Thyroid Association guidelines for further imaging (including 18F-DOPA PET/CT). METHODS: We prospectively recruited 18 patients with recurrent MTC, identified by elevation of Ct or CEA. Each patient underwent a 18F-FDG PET/CT and a 18F-DOPA PET/CT. RESULTS: Abnormal uptakes were detected with 18F-DOPA (n=12) and 18F-FDG (n=9), (sensitivity of 66.7% vs. 50%; p<0.01). Twenty-eight lesions were detected with 18F-DOPA vs. 16 lesions with 18F-FDG (1.56±1.5 vs. 0.89±1.18 lesions per patient; p=0.01). None of our patients showed additional lesions with 18F-FDG in comparison to 18F-DOPA. Patient-based detection rate increased significantly with Ct levels ≥150 pg/mL vs. Ct<150 pg/mL for both 18F-DOPA (sensitivity 90.9% vs. 28.6%; p=0.013) and 18F-FDG PET/CT (sensitivity 72.7% vs. 14.3%; p=0.025). Using a CEA cutoff of ≥5 ng/mL, detection rates of 18F-DOPA and 18F-FDG PET/CT were 81.1% and 72.7%, respectively. No correlation between Ct-DT or CEA-DT and PET positivity was found. Histological confirmation was obtained in eight patients. CONCLUSIONS: 18F-DOPA PET/CT appears to be superior to 18F-FDG PET/CT in detecting and locating lesions in patients with recurrent MTC. This technique tends to be especially useful in patients with negative results in other imaging modalities and Ct≥150 pg/mL or CEA≥5 ng/mL.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, et al. Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging. 2017. PMID: 28646462. doi:10.1007/s00259-017-3759-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。